DSM Biologics launches Australian biopharma manufacturing facility

DSM Biologics, a business unit of DSM Pharmaceutical Products, a global business providing cGMP custom manufacturing services across all facets of the pharmaceutical industry, has signed preliminary agreements with the Australian government to design, build and operate the first major Australia-based mammalian biopharmaceutical manufacturing facility, which will be located in Brisbane.
Register for free to listen to this article
Listen with Speechify
0:00
1:00

PARSIPPANY, N.J.—DSM Biologics, a business unit of DSMPharmaceutical Products, a global business providing cGMP custom manufacturingservices across all facets of the pharmaceutical industry, has signedpreliminary agreements with the Australian government to design, build andoperate the first major Australia-based mammalian biopharmaceuticalmanufacturing facility, which will be located in Brisbane. DSM Biologics willuse the 70,000-plus square-foot facility to offer mammalian process developmentand cGMP clinical and commercial manufacturing services to Australia andclients from all over the world. Among the services it currently offers aresmall-molecule API and intermediates manufacturing, fill/finish of parenteraland solid dosage forms and large-molecule drug substance production.

 

 

 

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.
Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue